Biotechnology
How can we prevent future pandemics and accelerate progress in the life sciences?
COVID-19 has revealed both strengths and weaknesses in response to biological threats. On the one hand, the pandemic exposed how weak and ineffectual our public health systems are at controlling highly contagious airborne respiratory diseases. On the other hand, the urgency of the moment — combined with decades of previous investment — enabled us to deliver mRNA vaccines in less than nine months. Biotechnology contains much more low-hanging fruit that is ripe to be picked — if only we can implement the right public policies.
Featured Publication
Biotechnology
Protect Human Subjects, Not Bureaucracy
How investigator choice in IRBs can improve ethical oversight
Read the full report
Biotechnology
Featured Publication
Protect Human Subjects, Not Bureaucracy
How investigator choice in IRBs can improve ethical oversight
Read the full report
Read our recent publications
Biotechnology
Weighing the Cost of the Pandemic
Knowing what we know now, how much damage did COVID-19 cause in the United States?
Read the full report
Biotechnology
Why BARDA Deserves More Funding
BARDA is uniquely positioned to defend the country against future pandemics and bioweapons
Read the full report
Biotechnology Research Team
Biotechnology
Creating Advance Market Commitments and Prizes for Pandemic Preparedness
Read the full report
